Oncocross, a South Korea-based drug developer, has raised SKr16.5bn ($14m) in its series B round co-led by Smilegate Investment, the corporate venturing unit (formerly known as MVP Venture Capital) of local games company Smilegate.
Other investors in the round included co-lead GN Tech Venture Capital, KDB Capital, Hana Financial Investment, Wooshin Venture Investment, Hanvit Investment, NAU IB Capital, Magna Investment, ID Ventures, KB Securities, SM Sino Technology Investment, Vision Creator and EBest Investment and Securities, according to DealStreetAsia.
Oncocross raised an undisclosed A round in July last year and has a partnership with Jeil Pharmaceutical to help develop its stroke treatment.
